| |
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
2026―Jun―12 |
Pathological potential of autoantibodies in long COVID |
Lucy Bird |
| 2 |
[GO] |
2024―Mrz―13 |
Author Correction: Using BCG vaccination to protect against COVID-19: when reality fails to meet expectation |
Laure F. Pittet, Christie C. A. Noble, Nicole L. Messina, Nigel Curtis |
| 3 |
[GO] |
2024―Jan―18 |
Using BCG vaccination to protect against COVID-19: when reality fails to meet expectation |
Laure F. Pittet, Christie C. A. Noble, Nicole L. Messina, Nigel Curtis |
| 4 |
[GO] |
2023―Nov―08 |
Gut fungi have lasting effect on immune response to severe COVID-19 |
Alexandra Flemming |
| 5 |
[GO] |
2023―Nov―07 |
Low serotonin linked to long COVID |
Lucy Bird |
| 6 |
[GO] |
2023―Okt―10 |
The distinctive immune features of long COVID |
Alexandra Flemming |
| 7 |
[GO] |
2023―Okt―06 |
Tracking the infant immune response to SARS-CoV-2 |
Yvonne Bordon |
| 8 |
[GO] |
2023―Sep―18 |
Author Correction: The immunology of long COVID |
Daniel M. Altmann, Emily M. Whettlock, Siyi Liu, Deepa J. Arachchillage, Rosemary J. Boyton |
| 9 |
[GO] |
2023―Sep―15 |
Lung-migrating helminths can enhance immunity to SARS-CoV-2 |
Yvonne Bordon |
| 10 |
[GO] |
2023―Jul―25 |
Asymptomatic SARS-CoV-2 linked to HLA-B*15:01 |
Yvonne Bordon |
| 11 |
[GO] |
2023―Jul―11 |
The immunology of long COVID |
Daniel M. Altmann, Emily M. Whettlock, Siyi Liu, Deepa J. Arachchillage, Rosemary J. Boyton |
| 12 |
[GO] |
2023―Mrz―14 |
Autoantibodies against chemokines linked with better disease outcomes in COVID-19 |
Yvonne Bordon |
| 13 |
[GO] |
2023―Mrz―14 |
Repurposing metabolic drugs for COVID-19 |
Yvonne Bordon |
| 14 |
[GO] |
2022―Dez―20 |
The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses |
Sam M. Murray, Azim M. Ansari, John Frater, Paul Klenerman, Susanna Dunachie, Eleanor Barnes, Ane Ogbe |
| 15 |
[GO] |
2022―Dez―20 |
Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines |
Yi Ju, Juan Manuel Carreño, Viviana Simon, Kenneth Dawson, Florian Krammer, Stephen J. Kent |
| 16 |
[GO] |
2022―Dez―19 |
Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection |
Ali Zhang, Hannah D. Stacey, Michael R. D’Agostino, Yona Tugg, Art Marzok, Matthew S. Miller |
| 17 |
[GO] |
2022―Dez―09 |
Unique properties of tissue-resident memory T cells in the lungs: implications for COVID-19 and other respiratory diseases |
Francis R. Carbone |
| 18 |
[GO] |
2022―Nov―08 |
‘Prime and spike’ induces mucosal immunity and reduces SARS-CoV-2 transmission |
Alexandra Flemming |
| 19 |
[GO] |
2022―Okt―05 |
COVID-19 and cellular senescence |
Clemens A. Schmitt, Tamar Tchkonia, Laura J. Niedernhofer, Paul D. Robbins, James L. Kirkland, Soyoung Lee |
| 20 |
[GO] |
2022―Sep―27 |
Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses |
Yanjia Chen, Xiaoyu Zhao, Hao Zhou, Huanzhang Zhu, Shibo Jiang, Pengfei Wang |
| 21 |
[GO] |
2022―Aug―09 |
SARS-CoV-2 hybrid immunity: silver bullet or silver lining? |
Rahul Suryawanshi, Melanie Ott |
| 22 |
[GO] |
2022―Aug―05 |
Understanding COVID-19-associated coagulopathy |
Edward M. Conway, Nigel Mackman, Ronald Q. Warren, Alisa S. Wolberg, Laurent O. Mosnier, Robert A. Campbell, Lisa E. Gralinski, Matthew T. Rondina, Frank L. van de Veerdonk, Karin M. Hoffmeister, John H. Griffin, Diane Nugent, Kyung Moon, James H. Morrissey |
| 23 |
[GO] |
2022―Jul―22 |
Vitamin D for COVID-19: where are we now? |
Adrian R. Martineau, Margherita T. Cantorna |
| 24 |
[GO] |
2022―Jul―13 |
Respiratory syncytial virus after the SARS-CoV-2 pandemic - what next? |
Lucy G. Mosscrop, Thomas C. Williams, John S. Tregoning |
| 25 |
[GO] |
2022―Jul―04 |
Considering innate immune responses in SARS-CoV-2 infection and COVID-19 |
Michael S. Diamond, John D. Lambris, Jenny P. Ting, John S. Tsang |
| 26 |
[GO] |
2022―Jun―29 |
When ‘mild’ COVID-19 is not so mild |
Kirsty Minton |
| 27 |
[GO] |
2022―Jun―29 |
Mechanistic insights into Long COVID in hamsters |
Kirsty Minton |
| 28 |
[GO] |
2022―Jun―10 |
Diabetes enhances viral loads in COVID-19 |
Alexandra Flemming |
| 29 |
[GO] |
2022―Jun―10 |
Vaccines only partially protect against Long COVID |
Alexandra Flemming |
| 30 |
[GO] |
2022―Jun―07 |
COVID-19 and Down syndrome: the spark in the fuel |
Manini Majithia, Susan P. Ribeiro |
| 31 |
[GO] |
2022―Mai―24 |
Cardiometabolic syndrome - an emergent feature of Long COVID? |
Justin J. Frere, Benjamin R. tenOever |
| 32 |
[GO] |
2022―Apr―28 |
Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast? |
Stephen J. Kent, David S. Khoury, Arnold Reynaldi, Jennifer A. Juno, Adam K. Wheatley, Eva Stadler, E. John Wherry, James Triccas, Sarah C. Sasson, Deborah Cromer, Miles P. Davenport |
| 33 |
[GO] |
2022―Apr―19 |
SARS-CoV-2: from herd immunity to hybrid immunity |
David Goldblatt |
| 34 |
[GO] |
2022―Apr―12 |
Estimating disease severity of Omicron and Delta SARS-CoV-2 infections |
Alex Sigal, Ron Milo, Waasila Jassat |
| 35 |
[GO] |
2022―Apr―08 |
Do individuals who have recovered from COVID-19 still benefit from being vaccinated? |
Alexandra Flemming |
| 36 |
[GO] |
2022―Mrz―31 |
ORF9c and ORF10 as accessory proteins of SARS-CoV-2 in immune evasion |
Milad Zandi |
| 37 |
[GO] |
2022―Mrz―28 |
Inflammatory cytokines and cardiac arrhythmias: the lesson from COVID-19 |
Pietro Enea Lazzerini, Franco Laghi-Pasini, Mohamed Boutjdir, Pier Leopoldo Capecchi |
| 38 |
[GO] |
2022―Mrz―18 |
SARS-CoV-2 infection and COVID-19 vaccination in pregnancy |
Victoria Male |
| 39 |
[GO] |
2022―Mrz―14 |
A new set of genes linked to critical COVID-19 |
Yvonne Bordon |
| 40 |
[GO] |
2022―Mrz―14 |
Comparing paediatric COVID-19 with MIS-C |
Yvonne Bordon |
| 41 |
[GO] |
2022―Mrz―14 |
Social distancing plus rapid vaccination prevents emergence of SARS-CoV-2 variants |
Yvonne Bordon |
| 42 |
[GO] |
2022―Feb―15 |
First glimpses into the mechanisms of Long COVID |
Alexandra Flemming |
| 43 |
[GO] |
2022―Feb―15 |
Lessons from Long COVID: working with patients to design better research |
Nisreen A. Alwan |
| 44 |
[GO] |
2022―Feb―10 |
Modelling vaccination strategies for COVID-19 |
Caroline E. Wagner, Chadi M. Saad-Roy, Bryan T. Grenfell |
| 45 |
[GO] |
2021―Dez―17 |
Author Correction: Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses - are we our own worst enemy? |
Lok-Yin Roy Wong, Stanley Perlman |
| 46 |
[GO] |
2021―Dez―15 |
The state of complement in COVID-19 |
Behdad Afzali, Marina Noris, Bart N. Lambrecht, Claudia Kemper |
| 47 |
[GO] |
2021―Dez―13 |
Author Correction: SARS-CoV-2 and HIV-1 - A Tale of Two Vaccines |
Barton F. Haynes |
| 48 |
[GO] |
2021―Dez―07 |
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact |
Marc Lipsitch, Florian Krammer, Gili Regev-Yochay, Yaniv Lustig, Ran D. Balicer |
| 49 |
[GO] |
2021―Dez―06 |
The germinal centre B cell response to SARS-CoV-2 |
Brian J. Laidlaw, Ali H. Ellebedy |
| 50 |
[GO] |
2021―Dez―06 |
Cross-reactive memory T cells abort SARS-CoV-2 infection |
Alexandra Flemming |
| 51 |
[GO] |
2021―Dez―03 |
Dexamethasone restrains neutrophils in severe COVID-19 |
Alexandra Flemming |
| 52 |
[GO] |
2021―Dez―03 |
Defective viral genomes can protect against SARS-CoV-2 variants and other respiratory viruses |
Alexandra Flemming |
| 53 |
[GO] |
2021―Nov―26 |
Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses - are we our own worst enemy? |
Lok-Yin Roy Wong, Stanley Perlman |
| 54 |
[GO] |
2021―Nov―05 |
Comparing neurological complications after COVID-19 vaccination and SARS-CoV-2 infection |
Alexandra Flemming |
| 55 |
[GO] |
2021―Nov―05 |
Foetal sex affects maternal and placental immune responses to SARS-CoV-2 |
Alexandra Flemming |
| 56 |
[GO] |
2021―Nov―05 |
SARS-CoV-2 Delta variant excels at membrane fusion, but not immune evasion |
Alexandra Flemming |
| 57 |
[GO] |
2021―Okt―19 |
The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions? |
Rosemary J. Boyton, Daniel M. Altmann |
| 58 |
[GO] |
2021―Okt―05 |
Cross-reactive tissue-resident CD8+ T cells may provide first line of defence against SARS-CoV-2 |
Alexandra Flemming |
| 59 |
[GO] |
2021―Sep―14 |
Negative impact of the COVID-19 pandemic on routine childhood immunization: experience from Pakistan |
Muhammad Suleman Rana, Aamer Ikram, Muhammad Salman, Muhammad Usman, Massab Umair |
| 60 |
[GO] |
2021―Sep―08 |
T cell-oriented strategies for controlling the COVID-19 pandemic |
Ji Yun Noh, Hye Won Jeong, Jerome H. Kim, Eui-Cheol Shin |
| 61 |
[GO] |
2021―Aug―10 |
Poor nasal immunity can lead to severe COVID-19 |
Alexandra Flemming |
| 62 |
[GO] |
2021―Aug―10 |
Detecting future coronavirus pandemics |
Alexandra Flemming |
| 63 |
[GO] |
2021―Aug―09 |
Inflammasome activation at the crux of severe COVID-19 |
Setu M. Vora, Judy Lieberman, Hao Wu |
| 64 |
[GO] |
2021―Aug―09 |
Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape |
John S. Tregoning, Katie E. Flight, Sophie L. Higham, Ziyin Wang, Benjamin F. Pierce |
| 65 |
[GO] |
2021―Aug―04 |
Publisher Correction: SARS-CoV-2 and HIV-1 - a tale of two vaccines |
Barton F. Haynes |
| 66 |
[GO] |
2021―Jul―16 |
SARS-CoV-2 and HIV-1 - a tale of two vaccines |
Barton F. Haynes |
| 67 |
[GO] |
2021―Jul―01 |
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans |
Manish Sadarangani, Arnaud Marchant, Tobias R. Kollmann |
| 68 |
[GO] |
2021―Jun―24 |
Understanding COVID-19 in Africa |
Sofonias K. Tessema, John N. Nkengasong |
| 69 |
[GO] |
2021―Mai―14 |
Single-cell atlases dissect tissue destruction by SARS-CoV-2 |
Alexandra Flemming |
| 70 |
[GO] |
2021―Mai―10 |
Author Correction: Will SARS-CoV-2 variants of concern affect the promise of vaccines? |
Ravindra K. Gupta |
| 71 |
[GO] |
2021―Apr―29 |
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection |
Deborah Cromer, Jennifer A. Juno, David Khoury, Arnold Reynaldi, Adam K. Wheatley, Stephen J. Kent, Miles P. Davenport |
| 72 |
[GO] |
2021―Apr―29 |
Will SARS-CoV-2 variants of concern affect the promise of vaccines? |
Ravindra K. Gupta |
| 73 |
[GO] |
2021―Apr―19 |
Neutralizing monoclonal antibodies for treatment of COVID-19 |
Peter C. Taylor, Andrew C. Adams, Matthew M. Hufford, Inmaculada de la Torre, Kevin Winthrop, Robert L. Gottlieb |
| 74 |
[GO] |
2021―Apr―14 |
Seeing SARS-CoV-2 variants through the eyes of T cells |
Aljawharah Alrubayyi, Dimitra Peppa |
| 75 |
[GO] |
2021―Apr―13 |
Is IL-6 a key cytokine target for therapy in COVID-19? |
Simon A. Jones, Christopher A. Hunter |
| 76 |
[GO] |
2021―Apr―06 |
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19 |
Aldo Bonaventura, Alessandra Vecchié, Lorenzo Dagna, Kimberly Martinod, Dave L. Dixon, Benjamin W. Van Tassell, Francesco Dentali, Fabrizio Montecucco, Steffen Massberg, Marcel Levi, Antonio Abbate |
| 77 |
[GO] |
2021―Apr―01 |
Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination |
Sarah Cobey, Daniel B. Larremore, Yonatan H. Grad, Marc Lipsitch |
| 78 |
[GO] |
2021―Mrz―15 |
The first 12 months of COVID-19: a timeline of immunological insights |
Thiago Carvalho, Florian Krammer, Akiko Iwasaki |
| 79 |
[GO] |
2021―Mrz―12 |
Author Correction: Are COVID-19 vaccines safe in pregnancy? |
Victoria Male |
| 80 |
[GO] |
2021―Mrz―05 |
COVID-19 vaccines: modes of immune activation and future challenges |
John R. Teijaro, Donna L. Farber |
| 81 |
[GO] |
2021―Mrz―03 |
Are COVID-19 vaccines safe in pregnancy? |
Victoria Male |
| 82 |
[GO] |
2021―Feb―23 |
SARS-CoV-2 infection and COVID-19 in asthmatics: a complex relationship |
Chrysanthi Skevaki, Antonina Karsonova, Alexander Karaulov, Daria Fomina, Min Xie, Sharon Chinthrajah, Kari C. Nadeau, Harald Renz |
| 83 |
[GO] |
2021―Feb―20 |
Author Correction: Do rogue antibodies make the difference between mild versus severe COVID-19? |
Alexandra Flemming |
| 84 |
[GO] |
2021―Feb―09 |
Targeting autoantibodies in COVID-19 |
Isabela Pedroza-Pacheco, Persephone Borrow |
| 85 |
[GO] |
2021―Feb―04 |
Do rogue antibodies make the difference between mild versus severe COVID-19? |
Alexandra Flemming |
| 86 |
[GO] |
2021―Feb―04 |
Intracranial inflammatory mediators involved in SARS-CoV-2 neurological manifestations? |
Alexandra Flemming |
| 87 |
[GO] |
2021―Feb―04 |
SARS-CoV-2 variant evades antibodies whilst maintaining fitness |
Alexandra Flemming |
| 88 |
[GO] |
2021―Jan―13 |
What have we learnt so far from COVID-19? |
Peter C. Doherty |
| 89 |
[GO] |
2021―Jan―11 |
Immune readouts from the Oxford COVID-19 vaccine |
Yvonne Bordon |
| 90 |
[GO] |
2021―Jan―11 |
Super(antigen) target for SARS-CoV-2 |
Matthew Brown, Nina Bhardwaj |
| 91 |
[GO] |
2021―Jan―05 |
Endemic SARS-CoV-2 will maintain post-pandemic immunity |
Marc Veldhoen, J. Pedro Simas |
| 92 |
[GO] |
2020―Dez―18 |
Viral targets for vaccines against COVID-19 |
Lianpan Dai, George F. Gao |
| 93 |
[GO] |
2020―Dez―01 |
Mapping host restriction of SARS-CoV-2 |
Ester Gea-Mallorquí |
| 94 |
[GO] |
2020―Dez―01 |
B cell persistence and evolution to SARS-CoV-2 |
Aljawharah Alrubayyi |
| 95 |
[GO] |
2020―Dez―01 |
Cross-viral protection against SARS-CoV-2? |
Sophie G. Reed |
| 96 |
[GO] |
2020―Nov―19 |
Leukocyte trafficking to the lungs and beyond: lessons from influenza for COVID-19 |
Ronen Alon, Mike Sportiello, Stav Kozlovski, Ashwin Kumar, Emma C. Reilly, Alexander Zarbock, Natalio Garbi, David J. Topham |
| 97 |
[GO] |
2020―Nov―02 |
Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models |
David S. Khoury, Adam K. Wheatley, Mitchell D. Ramuta, Arnold Reynaldi, Deborah Cromer, Kanta Subbarao, David H. O’Connor, Stephen J. Kent, Miles P. Davenport |
| 98 |
[GO] |
2020―Okt―21 |
Immunological considerations for SARS-CoV-2 human challenge studies |
Alexander D. Douglas, Adrian V. S. Hill |
| 99 |
[GO] |
2020―Okt―13 |
At the heart of COVID-19 |
Felix Clemens Richter |
| 100 |
[GO] |
2020―Okt―13 |
IL-18-dependent MAIT cell activation in COVID-19 |
Ester Gea-Mallorquí |
| 101 |
[GO] |
2020―Okt―13 |
Intestinal attenuation of COVID-19 inflammation |
Aljawharah Alrubayyi |
| 102 |
[GO] |
2020―Okt―06 |
Do cross-reactive antibodies cause neuropathology in COVID-19? |
Jakob Kreye, S. Momsen Reincke, Harald Prüss |
| 103 |
[GO] |
2020―Okt―06 |
Cross-reactive memory T cells and herd immunity to SARS-CoV-2 |
Marc Lipsitch, Yonatan H. Grad, Alessandro Sette, Shane Crotty |
| 104 |
[GO] |
2020―Okt―02 |
Fatty monocytes in COVID-19 |
Matthew D. Park |
| 105 |
[GO] |
2020―Okt―02 |
SARS-CoV-2 antibody seroconversion in care home |
Joan Shang, Alvaro Moreira |
| 106 |
[GO] |
2020―Sep―28 |
Keeping track of the SARS-CoV-2 vaccine pipeline |
Edward P. K. Parker, Madhumita Shrotri, Beate Kampmann |
| 107 |
[GO] |
2020―Sep―10 |
COVID-19 herd immunity: where are we? |
Arnaud Fontanet, Simon Cauchemez |
| 108 |
[GO] |
2020―Sep―10 |
The global response to the COVID-19 pandemic: how have immunology societies contributed? |
Faith Osier, Jenny P. Y. Ting, John Fraser, Bart N. Lambrecht, Marta Romano, Ricardo T. Gazzinelli, Karina R. Bortoluci, Dario S. Zamboni, Arne N. Akbar, Jennie Evans, Doug E. Brown, Kamala D. Patel, Yuzhang Wu, Ana B. Perez, Oliver Pérez, Thomas Kamradt, Christine Falk, Mira Barda-Saad, Amiram Ariel, Angela Santoni, Francesco Annunziato, Marco A. Cassatella, Hiroshi Kiyono, Valeriy Chereshnev, Alioune Dieye, Moustapha Mbow, Babacar Mbengue, Maguette D. S. Niang, Melinda Suchard |
| 109 |
[GO] |
2020―Sep―07 |
Coordinated and sustained immune memory responses after mild COVID-19 |
Aljawharah Alrubayyi |
| 110 |
[GO] |
2020―Sep―07 |
SARS-CoV-2 ORF9c: a mysterious membrane-anchored protein that regulates immune evasion? |
Fangfang Lu |
| 111 |
[GO] |
2020―Sep―07 |
Does a host restriction factor facilitate entry of SARS-CoV-2? |
Ester Gea-Mallorquí |
| 112 |
[GO] |
2020―Sep―04 |
Immunological considerations for COVID-19 vaccine strategies |
Mangalakumari Jeyanathan, Sam Afkhami, Fiona Smaill, Matthew S. Miller, Brian D. Lichty, Zhou Xing |
| 113 |
[GO] |
2020―Sep―01 |
Inhaled nanobodies against COVID-19 |
Gustavo Martinez-Delgado |
| 114 |
[GO] |
2020―Sep―01 |
Immune correlates of SARS-CoV-2 protection |
Matthew Brown |
| 115 |
[GO] |
2020―Sep―01 |
Long-lasting SARS-CoV-2-specific T cell memories |
Cansu Cimen Bozkus |
| 116 |
[GO] |
2020―Aug―24 |
Not just antibodies: B cells and T cells mediate immunity to COVID-19 |
Rebecca J. Cox, Karl A. Brokstad |
| 117 |
[GO] |
2020―Aug―21 |
Altered immune cell differentiation in the lungs of patients with critical COVID-19 |
Erinke van Grinsven, Kathrin Jansen |
| 118 |
[GO] |
2020―Aug―21 |
CD8+ T cells remember same bits of SARS-CoV-2 |
Julie M. Mazet, Ester Gea-Mallorquí |
| 119 |
[GO] |
2020―Aug―21 |
Attacking the defence: SARS-CoV-2 can infect immune cells |
Mariana Borsa, Julie M. Mazet |
| 120 |
[GO] |
2020―Aug―17 |
A cocktail of antibodies for COVID-19 therapy |
Dean B. Matthews |
| 121 |
[GO] |
2020―Aug―17 |
Shared CD8+ T cell receptors for SARS-CoV-2 |
Rachel Levantovsky, Verena van der Heide |
| 122 |
[GO] |
2020―Aug―17 |
Spatial resolution of SARS-CoV-2 lung infection |
Luisanna Pia |
| 123 |
[GO] |
2020―Aug―17 |
Author Correction: Pre-existing immunity to SARS-CoV-2: the knowns and unknowns |
Alessandro Sette, Shane Crotty |
| 124 |
[GO] |
2020―Aug―12 |
The type I interferon response in COVID-19: implications for treatment |
Jeong Seok Lee, Eui-Cheol Shin |
| 125 |
[GO] |
2020―Aug―11 |
Getting to the (germinal) centre of SARS-CoV-2 |
Felix Clemens Richter, Mariana Borsa |
| 126 |
[GO] |
2020―Aug―11 |
Antibody response to SARS-CoV-2 - sustained after all? |
Ewoud B. Compeer, Lion F. K. Uhl |
| 127 |
[GO] |
2020―Aug―11 |
SARS-CoV-2 vaccine - think globally, act locally |
Ester Gea-Mallorquí, Ewoud B. Compeer |
| 128 |
[GO] |
2020―Aug―10 |
After 62 years of regulating immunity, dexamethasone meets COVID-19 |
Derek W. Cain, John A. Cidlowski |
| 129 |
[GO] |
2020―Aug―10 |
Author Correction: Tissue damage from neutrophil-induced oxidative stress in COVID-19 |
Mireille Laforge, Carole Elbim, Corinne Frère, Miryana Hémadi, Charbel Massaad, Philippe Nuss, Jean- Jacques Benoliel, Chrystel Becker |
| 130 |
[GO] |
2020―Aug―04 |
Publisher Correction: NK cells in COVID-19: protectors or opponents? |
Aljawharah Alrubayyi |
| 131 |
[GO] |
2020―Jul―31 |
IgGs drive COVID-19 myeloid hyperinflammation |
Matthew D. Park |
| 132 |
[GO] |
2020―Jul―30 |
NK cells in COVID-19: protectors or opponents? |
Aljawharah Alrubayyi |
| 133 |
[GO] |
2020―Jul―29 |
Tissue damage from neutrophil-induced oxidative stress in COVID-19 |
Mireille Laforge, Carole Elbim, Corinne Frère, Miryana Hémadi, Charbel Massaad, Philippe Nuss, Jean-Jacques Benoliel, Chrystel Becker |
| 134 |
[GO] |
2020―Jul―29 |
T cell responses in patients with COVID-19 |
Zeyu Chen, E. John Wherry |
| 135 |
[GO] |
2020―Jul―20 |
Virus dissociated from inflammation in fatal COVID-19 |
Meriem Belabed |
| 136 |
[GO] |
2020―Jul―20 |
Antibody responses to SARS-CoV-2 short-lived |
Nicolas Vabret |
| 137 |
[GO] |
2020―Jul―10 |
T cell renaissance in COVID-19 |
Lee Garner, Liliana Cifuentes |
| 138 |
[GO] |
2020―Jul―10 |
CRISPRing for host genes regulating SARS-CoV-2 |
Fangfang Lu, Michael Tellier |
| 139 |
[GO] |
2020―Jul―10 |
SARS-CoV-2 on the neural battleground |
Clara Eléonore Pavillet, Tharini Ashtalakshmi Selvakumar |
| 140 |
[GO] |
2020―Jul―07 |
COVID-19 and influenza: preparing for the storm |
Matthew D. Park |
| 141 |
[GO] |
2020―Jul―07 |
SARS-CoV-2-specific T cells without antibodies |
Cansu Cimen Bozkus |
| 142 |
[GO] |
2020―Jul―07 |
Pre-existing immunity to SARS-CoV-2: the knowns and unknowns |
Alessandro Sette, Shane Crotty |
| 143 |
[GO] |
2020―Jul―02 |
A call to arms: helping family, friends and communities navigate the COVID-19 infodemic |
Heidi J. Larson |
| 144 |
[GO] |
2020―Jun―26 |
SARS-CoV-2: too infectious to handle? |
Clarissa Coveney, Jennifer Alderson |
| 145 |
[GO] |
2020―Jun―23 |
GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches |
Frederick M. Lang, Kevin M.-C. Lee, John R. Teijaro, Burkhard Becher, John A. Hamilton |
| 146 |
[GO] |
2020―Jun―22 |
Sex differences in immune responses in COVID-19 |
Matthew D. Park |
| 147 |
[GO] |
2020―Jun―22 |
Roles for eosinophils and basophils in COVID-19? |
Alexandra Tabachnikova, Steven T. Chen |
| 148 |
[GO] |
2020―Jun―22 |
Preclinical data from SARS-CoV-2 mRNA vaccine |
Nicolas Vabret |
| 149 |
[GO] |
2020―Jun―18 |
Severe COVID-19 in the young and healthy: monogenic inborn errors of immunity? |
Shen-Ying Zhang, Qian Zhang, Jean-Laurent Casanova, Helen C. Su |
| 150 |
[GO] |
2020―Jun―17 |
Optimizing safety surveillance for COVID-19 vaccines |
Rebecca E. Chandler |
| 151 |
[GO] |
2020―Jun―16 |
Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children |
Anne H. Rowley |
| 152 |
[GO] |
2020―Jun―12 |
A versatile mouse model of COVID-19 |
Helene Borrmann, Rachel E. Rigby |
| 153 |
[GO] |
2020―Jun―12 |
Publisher Correction: Risk factors for death from COVID-19 |
Myvizhi Esai Selvan |
| 154 |
[GO] |
2020―Jun―12 |
Passive antibody therapy in COVID-19 |
Jonathan Abraham |
| 155 |
[GO] |
2020―Jun―12 |
Author Correction: Complement as a target in COVID-19? |
Antonio M. Risitano, Dimitrios C. Mastellos, Markus Huber-Lang, Despina Yancopoulou, Cecilia Garlanda, Fabio Ciceri, John D. Lambris |
| 156 |
[GO] |
2020―Jun―12 |
SARS-CoV-2 has a sweet tooth |
Athena Cavounidis, Elizabeth H. Mann |
| 157 |
[GO] |
2020―Jun―11 |
Considering how biological sex impacts immune responses and COVID-19 outcomes |
Eileen P. Scully, Jenna Haverfield, Rebecca L. Ursin, Cara Tannenbaum, Sabra L. Klein |
| 158 |
[GO] |
2020―Jun―08 |
Dissecting antibody-mediated protection against SARS-CoV-2 |
Tomer Zohar, Galit Alter |
| 159 |
[GO] |
2020―Jun―05 |
Many paths to COVID-19 lymphocyte dysfunction |
Samarth Hegde |
| 160 |
[GO] |
2020―Jun―05 |
SARS-CoV-2 cross-reactivity in healthy donors |
Verena van der Heide |
| 161 |
[GO] |
2020―Jun―05 |
Immune evasion via SARS-CoV-2 ORF8 protein? |
Matthew D. Park |
| 162 |
[GO] |
2020―Jun―04 |
COVID-19 vaccines: neutralizing antibodies and the alum advantage |
Peter J. Hotez, David B. Corry, Ulrich Strych, Maria Elena Bottazzi |
| 163 |
[GO] |
2020―Jun―04 |
Author Correction: COVID-19: the vasculature unleashed |
Laure-Anne Teuwen, Vincent Geldhof, Alessandra Pasut, Peter Carmeliet |
| 164 |
[GO] |
2020―Jun―02 |
Blood clots and TAM receptor signalling in COVID-19 pathogenesis |
Greg Lemke, Gregg J. Silverman |
| 165 |
[GO] |
2020―Jun―02 |
Author Correction: Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages |
Miriam Merad, Jerome C. Martin |
| 166 |
[GO] |
2020―Mai―27 |
Risk factors for death from COVID-19 |
Myvizhi Esai Selvan |
| 167 |
[GO] |
2020―Mai―27 |
Kawasaki disease linked to COVID-19 in children |
Alvaro Moreira |
| 168 |
[GO] |
2020―Mai―27 |
Innate T cells in COVID-19: friend or foe? |
Verena van der Heide |
| 169 |
[GO] |
2020―Mai―26 |
Dysregulation of type I interferon responses in COVID-19 |
Dhiraj Acharya, GuanQun Liu, Michaela U. Gack |
| 170 |
[GO] |
2020―Mai―21 |
COVID-19: the vasculature unleashed |
Laure-Anne Teuwen, Vincent Geldhof, Alessandra Pasut, Peter Carmeliet |
| 171 |
[GO] |
2020―Mai―14 |
Modulation of immune crosstalk in COVID-19 |
Bérengère Salomé, Zafar Mahmood |
| 172 |
[GO] |
2020―Mai―14 |
SARS-CoV-2 likes it cool |
Alessandra Soares-Schanoski |
| 173 |
[GO] |
2020―Mai―11 |
BCG-induced trained immunity: can it offer protection against COVID-19? |
Luke A. J. O’Neill, Mihai G. Netea |
| 174 |
[GO] |
2020―Mai―06 |
Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages |
Miriam Merad, Jerome C. Martin |
| 175 |
[GO] |
2020―Mai―01 |
Will helminth co-infection modulate COVID-19 severity in endemic regions? |
Richard S. Bradbury, David Piedrafita, Andrew Greenhill, Siddhartha Mahanty |
| 176 |
[GO] |
2020―Mai―01 |
COVID-19: a case for inhibiting IL-17? |
Omar Pacha, Mary Alice Sallman, Scott E. Evans |
| 177 |
[GO] |
2020―Apr―30 |
Impaired interferon signature in severe COVID-19 |
Conor Gruber |
| 178 |
[GO] |
2020―Apr―30 |
Inactivated vaccine for SARS-CoV-2 |
Emma Risson |
| 179 |
[GO] |
2020―Apr―30 |
SARS-CoV-2-reactive T cells in patients and healthy donors |
Luisanna Pia |
| 180 |
[GO] |
2020―Apr―28 |
Neutralizing antibody response in mild COVID-19 |
Verena van der Heide |
| 181 |
[GO] |
2020―Apr―28 |
COVID-19 vaccine design: the Janus face of immune enhancement |
Peter J. Hotez, David B. Corry, Maria Elena Bottazzi |
| 182 |
[GO] |
2020―Apr―28 |
Cancer therapy tool informs COVID-19 vaccines |
Miriam Saffern |
| 183 |
[GO] |
2020―Apr―28 |
Does asthma make COVID-19 worse? |
Samarth Hegde |
| 184 |
[GO] |
2020―Apr―28 |
The trinity of COVID-19: immunity, inflammation and intervention |
Matthew Zirui Tay, Chek Meng Poh, Laurent Rénia, Paul A. MacAry, Lisa F. P. Ng |
| 185 |
[GO] |
2020―Apr―23 |
Complement as a target in COVID-19? |
Antonio M. Risitano, Dimitrios C. Mastellos, Markus Huber-Lang, Despina Yancopoulou, Cecilia Garlanda, Fabio Ciceri, John D. Lambris |
| 186 |
[GO] |
2020―Apr―23 |
Advancing scientific knowledge in times of pandemics |
Nicolas Vabret, Robert Samstein, Nicolas Fernandez, Miriam Merad |
| 187 |
[GO] |
2020―Apr―21 |
The potential danger of suboptimal antibody responses in COVID-19 |
Akiko Iwasaki, Yexin Yang |
| 188 |
[GO] |
2020―Apr―17 |
Macrophages: a Trojan horse in COVID-19? |
Matthew D. Park |
| 189 |
[GO] |
2020―Apr―17 |
Will we see protection or reinfection in COVID-19? |
Miyo Ota |
| 190 |
[GO] |
2020―Apr―17 |
A map of SARS-CoV-2 and host cell interactions |
Louise Malle |
| 191 |
[GO] |
2020―Apr―15 |
COVID-19: risk for cytokine targeting in chronic inflammatory diseases? |
Georg Schett, Michael Sticherling, Markus F. Neurath |
| 192 |
[GO] |
2020―Apr―14 |
Coronaviruses hijack the complement system |
C. Matthias Wilk |
| 193 |
[GO] |
2020―Apr―14 |
Human antibodies can neutralize SARS-CoV-2 |
Jovani Catalan-Dibene |
| 194 |
[GO] |
2020―Apr―09 |
COVID-19: immunopathology and its implications for therapy |
Xuetao Cao |
| 195 |
[GO] |
2020―Apr―06 |
Dysregulation of lung myeloid cells in COVID-19 |
Bérengère Salomé, Assaf Magen |
| 196 |
[GO] |
2020―Apr―06 |
In the eye of the COVID-19 cytokine storm |
Natalie Vaninov |
| 197 |
[GO] |
2020―Apr―06 |
Fighting COVID-19 exhausts T cells |
Chang Moon |
